HomeCompareSTON vs MRK

STON vs MRK: Dividend Comparison 2026

STON yields 778.05% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STON wins by $763.1K in total portfolio value
10 years
STON
STON
● Live price
778.05%
Share price
$3.53
Annual div
$27.47
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$820.8K
Annual income
$3,158.23
Full STON calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — STON vs MRK

📍 STON pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTONMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STON + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STON pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STON
Annual income on $10K today (after 15% tax)
$66,134.58/yr
After 10yr DRIP, annual income (after tax)
$2,684.50/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $5,912.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STON + MRK for your $10,000?

STON: 50%MRK: 50%
100% MRK50/50100% STON
Portfolio after 10yr
$439.3K
Annual income
$6,636.01/yr
Blended yield
1.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

STON
Analyst Ratings
1
Buy
3
Hold
Consensus: Hold
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STON buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTONMRK
Forward yield778.05%2.81%
Annual dividend / share$27.47$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$820.8K$57.7K
Annual income after 10y$3,158.23$10,113.78
Total dividends collected$524.1K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: STON vs MRK ($10,000, DRIP)

YearSTON PortfolioSTON Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$49,603$38,902.69$11,213$373.04+$38.4KSTON
2$143,247$90,171.88$12,667$512.06+$130.6KSTON
3$274,959$121,684.96$14,439$708.14+$260.5KSTON
4$403,352$109,145.60$16,640$988.16+$386.7KSTON
5$506,405$74,818.41$19,432$1,394.07+$487.0KSTON
6$585,747$43,894.34$23,057$1,992.90+$562.7KSTON
7$650,475$23,725.06$27,889$2,894.79+$622.6KSTON
8$708,320$12,311.58$34,518$4,286.29+$673.8KSTON
9$764,167$6,264.68$43,912$6,494.35+$720.3KSTON
10$820,817$3,158.23$57,714$10,113.78+$763.1KSTON

STON vs MRK: Complete Analysis 2026

STONStock

StoneMor Inc. owns and operates cemeteries and funeral homes in the United States. The company operates in two segments, Cemetery Operations and Funeral Home Operations. The Cemetery Operations segment provides cemetery property interment rights, such as burial lots, lawn and mausoleum crypts, and cremation niches; cemetery merchandise comprising burial vaults, caskets, grave markers, and memorials; and cemetery services, which include opening and closing, cremation, and cemetery merchandise installation services. The Funeral Home Operations segment offers caskets and other funeral related items; and funeral home services, such as family consultation, the removal and preparation of remains, insurance products, and the use of funeral home facilities for visitation and memorial services. As of March 30, 2022, it owned and operated 304 cemeteries and 72 funeral homes in 24 states and Puerto Rico Rico. The company was incorporated in 2004 and is headquartered in Bensalem, Pennsylvania.

Full STON Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this STON vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STON vs SCHDSTON vs JEPISTON vs OSTON vs KOSTON vs MAINSTON vs JNJSTON vs ABBVSTON vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.